Adenoviral vector vaccines in development for COVID: Data Byte

The future of adenoviral vector vaccines for COVID-19 has been further clouded after rare blood clotting events were associated with two of the four authorized adenovirus vaccines. At least a dozen other vaccines that employ adenovirus vectors are in clinical or preclinical development for COVID.

Though it’s not yet clear what is causing the rare thromboembolic events, autoimmune reactions to the vectors used in Janssen COVID-19 Vaccine from Johnson & Johnson (NYSE:JNJ) and Vaxzevria from AstraZeneca plc (LSE:AZN; NASDAQ:AZN) are suspected...